Spinocerebellar ataxia, SCA, affects balance, coordination, and muscle control. As the condition progresses, people can lose the ability to walk and speak - yet no approved treatment exists. Biohaven’s experimental therapy, troriluzole, now under review by the FDA, offers new hope by targeting glutamate imbalance, a key factor in the disease. Daniel Levine spoke with Melissa Wolfe Beiner, Senior Medical Director at Biohaven, on this week's #RARECast about spinocerebellar ataxia, their potential breakthrough, and why it could impact other neurological conditions as well. #RareDisease #SpinocerebellarAtaxia #Neurodegeneration #Biohaven #CareAboutRare #GlobalGenes
